These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 15933616)

  • 21. Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes.
    Fineman MS; Shen LZ; Taylor K; Kim DD; Baron AD
    Diabetes Metab Res Rev; 2004; 20(5):411-7. PubMed ID: 15343588
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Exenatide--an incretin mimetic for treatment of diabetes mellitus type 2].
    Musch A; Heinzl S
    Med Monatsschr Pharm; 2006 Mar; 29(3):86-9. PubMed ID: 16550880
    [No Abstract]   [Full Text] [Related]  

  • 23. Use of exenatide for weight loss in patients with diabetes.
    Virji A
    Am Fam Physician; 2007 May; 75(9):1304. PubMed ID: 17511061
    [No Abstract]   [Full Text] [Related]  

  • 24. Challenges and strategies for moving patients to injectable medications.
    Siminerio L
    Diabetes Educ; 2006; 32 Suppl 2():82S-90S. PubMed ID: 16554432
    [No Abstract]   [Full Text] [Related]  

  • 25. Exenatide: pancreatitis. Watch out for nausea and vomiting.
    Prescrire Int; 2008 Jun; 17(95):112. PubMed ID: 18630353
    [No Abstract]   [Full Text] [Related]  

  • 26. Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes.
    Linnebjerg H; Kothare PA; Skrivanek Z; de la Peña A; Atkins M; Ernest CS; Trautmann ME
    Diabet Med; 2006 Mar; 23(3):240-5. PubMed ID: 16492205
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Time for clinically relevant comparative effectiveness studies in type 2 diabetes.
    Nathan DM
    Ann Intern Med; 2011 Jan; 154(2):131-2. PubMed ID: 21135287
    [No Abstract]   [Full Text] [Related]  

  • 28. [Type 2 diabetic patient with reduced beta-cell function. New substance class: incretin-mimetics].
    MMW Fortschr Med; 2005 Aug; 147(31-32):55. PubMed ID: 16128203
    [No Abstract]   [Full Text] [Related]  

  • 29. Exenatide added to insulin. Beware the potentially serious adverse effects of exenatide.
    Prescrire Int; 2013 Jun; 22(139):151. PubMed ID: 23885352
    [No Abstract]   [Full Text] [Related]  

  • 30. Exenatide for once-weekly administration.
    Drug Ther Bull; 2012 Jul; 50(7):78-80. PubMed ID: 22789767
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Blood sugar and pounds down, hardly hypoglycemias. New generation of antidiabetics ante portas].
    Einecke D
    MMW Fortschr Med; 2006 Aug; 148(35-36):4-6, 8, 10. PubMed ID: 16995353
    [No Abstract]   [Full Text] [Related]  

  • 32. Exenatide therapy in insulin-treated type 2 diabetes and obesity.
    Nayak UA; Govindan J; Baskar V; Kalupahana D; Singh BM
    QJM; 2010 Sep; 103(9):687-94. PubMed ID: 20624837
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glucagon-like peptide-1 analogues for type 2 diabetes.
    Wilding JP; Hardy K
    BMJ; 2011 Feb; 342():d410. PubMed ID: 21325387
    [No Abstract]   [Full Text] [Related]  

  • 34. Exenatide: a novel incretin mimetic agent for treating type 2 diabetes mellitus.
    Lam S; See S
    Cardiol Rev; 2006; 14(4):205-11. PubMed ID: 16788334
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Exenatide and rare adverse events.
    Cure P; Pileggi A; Alejandro R
    N Engl J Med; 2008 May; 358(18):1969-70; discussion 1971-2. PubMed ID: 18450614
    [No Abstract]   [Full Text] [Related]  

  • 36. [Treatment of type 2 diabetes with new oral antihyperglycaemic drugs].
    Seissler J
    MMW Fortschr Med; 2008 May; 150(18):27-31. PubMed ID: 18533605
    [No Abstract]   [Full Text] [Related]  

  • 37. Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes.
    Ghofaili KA; Fung M; Ao Z; Meloche M; Shapiro RJ; Warnock GL; Elahi D; Meneilly GS; Thompson DM
    Transplantation; 2007 Jan; 83(1):24-8. PubMed ID: 17220786
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of an oral drug (acetaminophen) administered at various times in relation to subcutaneous injection of exenatide (exendin-4) in healthy subjects.
    Blase E; Taylor K; Gao HY; Wintle M; Fineman M
    J Clin Pharmacol; 2005 May; 45(5):570-7. PubMed ID: 15831781
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration.
    Gedulin BR; Smith PA; Jodka CM; Chen K; Bhavsar S; Nielsen LL; Parkes DG; Young AA
    Int J Pharm; 2008 May; 356(1-2):231-8. PubMed ID: 18291606
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exenatide: clinical aspects of the first incretin-mimetic for the treatment of type 2 diabetes mellitus.
    Wajcberg E; Tavaria A
    Expert Opin Pharmacother; 2009 Jan; 10(1):135-42. PubMed ID: 19236187
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.